DXVX

180400KOSDAQ기타 과학기술 서비스업

54.0 / 100

Reference Date: 2026-04-13

Financial Score9.0 / 40

News Sentiment17.0 / 25

Momentum18.0 / 20

Disclosure10.0 / 15

AI Analysis: Revenue is on a declining trend, Operating Profit is on a declining trend. Rose 10.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

DXVX is a biopharmaceutical company specializing in medical diagnostics, healthcare, and drug development, expanding globally through the 2022 acquisition of Hanbio Pharm and the 2023 establishment of a Chinese subsidiary. In medical diagnostics, it leverages NGS and AI-based platforms with GMP-certified facilities, while its drug development focuses on oncology therapies through partnerships with Stanford University and the acquisition of Evexis Gen. The company plans to mitigate financial risks by licensing technologies to major pharmaceutical firms.

Number of Employees

62people

Average Salary

107.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 16.504.0Point

PBR

5.07Industry Average 3.011.0Point

1.7x industry avg (risky)

ROE

-52.77Industry Average -0.673.5Point

78.8x industry avg (excellent)

Debt Ratio

39.00Industry Average 25.420.5Point

1.5x industry avg (risky)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼20.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼45.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -123.0% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 3Neutral 0Negative 0Average Sentiment Score 80

Positive
DXVX, 바이오유럽에서 ‘먹는 비만약’ 알리기 총력
DXVX가 바이오유럽 스프링에 참석해 다국적 제약사 및 신약치료제 개발사를 대상으로 먹는 비만치료제 기술을 알리고 파트너십을 진행했다는 뉴스이다.
Positive
DXVX, 바이오 유럽 스프링 참가…"글로벌 기술이전 집중 논의"
DXVX가 '2026 바이오 유럽 스프링'에 참가하여 신약 파이프라인 및 혁신 플랫폼에 대한 글로벌 기술이전 논의에 집중할 예정이라는 뉴스이다.
Positive
디엑스앤브이엑스, ‘바이오-유럽’ 참가…글로벌 기술수출 논의 집중
디엑스앤브이엑스가 유럽 최대 규모의 제약·바이오 콘퍼런스에 참가해 글로벌 기업들과 핵산 안정화 및 경구 비만약 등 기술수출을 위한 심도 있는 논의를 진행한다는 뉴스이다.

Detailed Momentum

52-week position8.0Point

Near 52w high (94%, uptrend)

Current 4,930Won52-week high 5,11052-week low 1,653

1-month return5.0Point

1m +10.79% (rising)

Volume trend5.0Point

Volume flat

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-10
Neutral주식등의대량보유상황보고서(일반)2026-04-10
Neutral주식등의대량보유상황보고서(일반)2026-04-07
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07